Innofend
Next-generation vaccine platform for pandemic viruses: a proprietary enterovirus platform using virus-like particles (VLP) to trigger a protective immune response, including against viruses traditional vaccine methods can't reach.
The row
- Stage
- Pre-revenue — No sales yet
- Location
- Ylöjärvi
- Founded
- 2025
- Research origin
- Tampere University
- Business ID
- 3513349-5 · Finnish trade register
Links
Where this sits on the map
Innofend is one of 33 companies in Therapeutics & Diagnostics. The others:
How this row was decided
Every row on this map is checked by hand against the trade register and the company's own material, and placed in the sector that best describes its business or its technology. Service firms and consultancies are left out, however advanced the technology they work with — the test is where the revenue comes from. Only funding figures the company or its investor has published are shown. The full rules are on the landscape ↗